Page 7 - Tim Boreham News Today

Tim Boreham is a freelance business writer and columnist, contributing to both major and niche publications on a variety of topics including sustainability issues.

Forecasts for zinc are as bullish as ever, with the USA declaring it a 'critical' mineral, but are investors paying attention?

Tim Boreham highlights the global addressable market opportunity for Avita Medical's skin graft technology, made famous by the Bali bombings

Tim Boreham highlights opportunities for SaaS company Alcidion, which tracks patients through the medical system

2022 has seen a sudden burst of listed hydrogen pure-plays, largely out of nowhere. Tim Boreham investigates

Actinogen Medical is a biotech with a potentially "gazillion" dollar opportunity in its Alzheimer's drug

Medical imaging is back in demand in the post-covid world and Mach7 Technologies seems an undervalued player

Having brought a canine cancer treatment to market, Qbiotic's focus has returned to treating two-legged cancers including melanoma and other difficult-to-treat cancers

Tom Boreham notes small caps with cash on the balance sheet are the safer bet compared to ‘pre-revenue' companies, and highlights several examples

Dr Boreham’s Crucible: Go Woke, go broke? Early signs say no concerns with this pyschedelic IPO